Sugi Predict

Sugi Predict / Compounds / SCHEMBL359832

SCHEMBL359832

SCHEMBL359832

CC(C)(C)OC(=O)N1CCC2(CCC(=O)CO2)CC1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ GPR119 Q8TDV5 6/20 0.43
▸ DDB1 Q16531 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ HRH3 Q9Y5N1 1/20 0.39
▸ AVPR1A P37288 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ RECQL P46063 1/20 0.38
▸ PDK4 Q16654 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ NR1H2 P55055 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23611994 0.93 USP2 (0.40) USP2SMN1; SMN2GPR119DDB1CRBN
SCHEMBL2428542 0.87 USP2 (0.46) USP2SMN1; SMN2GPR119DDB1CRBN
SCHEMBL21636212 0.83 USP2 (0.42) USP2SMN1; SMN2GPR119DDB1CRBN
SCHEMBL23881382 0.83 USP2 (0.42) USP2SMN1; SMN2GPR119DDB1CRBN
SCHEMBL23881383 0.83 USP2 (0.42) USP2SMN1; SMN2GPR119DDB1CRBN
SCHEMBL20975414 0.82 GPR119 (0.41) USP2SMN1; SMN2GPR119NR1H2
SCHEMBL14239663 0.81 USP2 (0.45) USP2SMN1; SMN2GPR119RECQL
SCHEMBL18053621 0.81 USP2 (0.59) USP2SMN1; SMN2GPR119RECQL
SCHEMBL2142558 0.80 USP2 (0.42) USP2SMN1; SMN2GPR119DDB1CRBN
SCHEMBL4689251 0.80 GPR119 (0.49) USP2SMN1; SMN2GPR119DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENT OF THE UNIV OF MICHIGAN (US) 2026-01-29 — — US disclosed
US-20250195484-A1 CEREBLON LIGANDS AND USES THEREOF UNIV MICHIGAN (US) 2025-06-19 — — US disclosed
EP-4554948-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS Regents of the University of Michigan (US) 2025-05-21 — — EP disclosed
EP-4499616-A1 SPIROBICYCLIC COMPOUNDS Acerand Therapeutics (Hong Kong) Limited (HK) 2025-02-05 — — EP disclosed
CN-119013260-A Spirobicyclic compounds 优领医药科技(香港)有限公司 2024-11-22 — — CN disclosed
WO-2024091370-A1 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2024-05-02 — — WO disclosed
WO-2024015412-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-01-18 — — WO disclosed
WO-2024015408-A1 INDAZOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENTS OF THE UNIVESITY OF MICHIGAN (US) 2024-01-18 — — WO disclosed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
WO-2023183607-A1 CEREBLON LIGANDS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-09-28 — — WO disclosed
US-20230115274-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-04-13 — — US disclosed
US-20210309669-A1 Heterocyclic Spiro Compounds As MAGL Inhibitors PFIZER INC. (US) 2021-10-07 — — US disclosed
US-20210309669-A1 Heterocyclic Spiro Compounds As MAGL Inhibitors PFIZER INC. (US) 2021-10-07 — — US disclosed
WO-2021138419-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC, (US) 2021-07-08 — — WO disclosed
WO-2020016710-A1 HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS PFIZER INC. (US) 2020-01-23 — — WO disclosed
US-20140309220-A1 BENZOXAZINES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2014-10-16 — — US disclosed
US-20140309220-A1 BENZOXAZINES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2014-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195484-A1 CEREBLON LIGANDS AND USES THEREOF CRBN, CDR2, CHLSN USP2 58/4885SMN1; SMN2 1764/4885GPR119 1654/4885
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, ESRRB USP2 1857/4885SMN1; SMN2 2810/4885GPR119 602/4885
US-20230115274-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 USP2 2289/4885SMN1; SMN2 2298/4885GPR119 749/4885
US-20140309220-A1 BENZOXAZINES AS MODULATORS OF ION CHANNELS KCNJ1, KCNJ2, KCNJ11 USP2 3920/4885SMN1; SMN2 975/4885GPR119 908/4885
US-20210309669-A1 Heterocyclic Spiro Compounds As MAGL Inhibitors MAG, ECH1, ECHS1 USP2 4431/4885SMN1; SMN2 219/4885GPR119 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.